- Home
- Companies
- cayman islands
- disease target
Show results for
Refine by
Disease Target Suppliers Serving Cayman Islands
36 companies found
based inSeoul, SOUTH KOREA
PROTIA Inc. aims to contribute to human health and well-being through finding new protein targets for disease prediction, early diagnosis, and development of new medicines. Based on our dedication for identification of bio-markers needed in early ...
based inUpton-Upon-Severn, UNITED KINGDOM
Established in 1979, Bio-Diagnostics is privately owned, rapidly growing, UK bio-tech business, based 40 miles south west of Birmingham, UK. Bio-Diagnostics is highly regarded and trusted globally, working closely with partners providing, ...
based inBoston, MASSACHUSETTS (USA)
Neoclease is at the forefront of advancing gene editing technologies with a mission to transform healthcare by curing genetic diseases rather than just treating them. Utilizing a bespoke approach, the company develops tailored nucleases designed to ...
based inOxford, UNITED KINGDOM
Founded in 2012, we are the leading pharmatech company and the first to automate drug discovery. As a full stack AI drug discovery company, we generate our own data before combining the analytical power of AI with the creativity and expertise of our ...
Target selection is key to creating success in drug discovery. Selecting each target is a significant decision and the future success of any molecule will depend on that initial ...
based inLondon, UNITED KINGDOM
At Benevolent we build technology in the service of science - to augment human intelligence and inspire the discovery of new medicines for the thousands of diseases that have no treatment. Building the right team is an art not a science. We strive ...
The Benevolent Platform™ is our powerful computational R&D platform. At its core sits our Knowledge Graph, which captures the interconnectivity of all relevant available data and scientific literature. Our suite of ...
based inBundoora, AUSTRALIA
AdAlta is an innovative, clinical stage biotech company developing a unique range of new drug treatments. AdAlta has pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, discovered initially in sharks and ...
AdAlta is utilising the power of the i-body technology platform to develop a growing pipeline of i-bodies to treat a range of conditions, with an initial focus on treating fibrotic diseases. AdAlta identified an i-body that binds to ...
based inHuesca, SPAIN
Vitassay develops and distributes reliable and certified solutions for the early detection of different pathogens which cause infectious diseases in humans. Our greatest asset is to offer a complete service for every customer to exceed their ...
based inWellesley Heights, MASSACHUSETTS (USA)
Novel point-of-care diagnostics for earlier disease detection. SANO Diagnostics is developing a range of disposable, cost-effective point-of-care diagnostics to detect the early onset of inflammation in several disease states. We are a development ...
based inCambridge, MASSACHUSETTS (USA)
Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be ...
based inLexington, MASSACHUSETTS (USA)
Fractyl Health is an organ editing metabolic therapeutics company focused on pioneering a new approach to the treatment of Type 2 Diabetes (T2D). Our goal is to transform T2D treatment from chronic blood glucose management to disease-modifying ...
based inSouth Melbourne, AUSTRALIA
BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. Our business model is to generate income from partnerships including with other vaccine and infectious ...
based inBoca Raton, FLORIDA (USA)
Entero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted, orally delivered therapies for gastrointestinal (GI) diseases. At the core of its research are three proprietary technologies. Latiglutenase is an ...
based inNew York, NEW YORK (USA)
miR Scientific, LLC is a healthcare company committed to transforming global cancer management by providing early and highly accurate detection, characterization, and monitoring of disease. The Company has developed the miR Disease Management ...
based inGangnam-gu, SOUTH KOREA
MitoImmune Therapeutics Inc. is a drug discovery and development biotech company that harnesses the power of mitochondria and its proprietary technology targeting mitochondria as the source for developing new potential breakthrough therapeutics. Our ...
based inEschborn, GERMANY
When we looked at the decision making landscape in organizations and observed that the available technologies and models were helping make decisions but with fixed cycles of information processing, running in batches, with little flexibility and ...
Ontosight Explore enables the exploration, detection and building of various direct and in-direct connections between drug, target, pathway and disease. We leverage a biological network model using enhanced natural ...
based inNorth Chicago, ILLINOIS (USA)
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people™s lives across several key therapeutic areas: ...
based inMechelen, BELGIUM
Galapagos discovers, develops and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through to Phase 3 programs in inflammation, fibrosis, and other indications. Our first medicine is approved and ...
based inAbingdon, UNITED KINGDOM
Thermally Stable Needle Free Solid Dose Vaccines. Enesi Pharma is developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax technologies. These diseases affect millions of ...
based inBasel, SWITZERLAND
EsoCap’s vision is to improve the lives of patients affected by esophageal diseases. The esophagus is a particularly challenging environment, as swallowed drugs only remain in the area between the mouth and the stomach for a few seconds. EsoCap, a ...
